Home Alzheimer’s Disease Strategies Combining Nivolumab Show Promise for Classic Hodgkin Lymphoma

Strategies Combining Nivolumab Show Promise for Classic Hodgkin Lymphoma

In a study of 2 experimental, nivolumab (Opdivo)-based, first-line treatment strategies in patients with early-stage unfavorable classic Hodgkin lymphoma, published in JAMA Oncology, researchers found that both strategies combining nivolumab and doxorubicin (Adriamycin), vinblastine (Velban), and dacarbazine (AVD) were feasible, highly effective, and resulted in excellent 12-month progression-free survival (PFS), they wrote.

“We observed early and sustained responses in both treatment groups and an unexpectedly high interim CR rate even after 4 doses of nivolumab alone,” the authors wrote. “Anti-PD-1-based first-line treatment of early-stage (classic Hodgkin lymphoma) warrants further evaluation within future trials, comparing a fully concomitant treatment with standard of care or an individualized approach with sequential anti-PD-1 treatment guided, e.g., by interim…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments